BRPI0516265A - composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente - Google Patents
composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmenteInfo
- Publication number
- BRPI0516265A BRPI0516265A BRPI0516265-3A BRPI0516265A BRPI0516265A BR PI0516265 A BRPI0516265 A BR PI0516265A BR PI0516265 A BRPI0516265 A BR PI0516265A BR PI0516265 A BRPI0516265 A BR PI0516265A
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic agent
- liposomes
- composition
- liposome
- retention
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 10
- 229940124597 therapeutic agent Drugs 0.000 title abstract 8
- 239000002502 liposome Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000014759 maintenance of location Effects 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 abstract 2
- 229910001431 copper ion Inorganic materials 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000002555 ionophore Substances 0.000 abstract 2
- 230000000236 ionophoric effect Effects 0.000 abstract 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 2
- 229960004768 irinotecan Drugs 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSICãO, USO DA MESMA, MéTODO DE AUMENTAR A RETENçãO DE UM AGENTE TERAPêUTICO DENTRO DOS LIPOSSOMAS, FORMULAçãO LIPOSSOMAL, E, USO DE UM AGENTE TERAPêUTICO ENCAPSULADO LIPOSSOMALMENTE. A presente invenção refere-se ao uso de íons de cobre, para obter-se retenção aumentada de um agente terapêutico dentro de um lipossoma. A invenção pode ser empregada para mais eficientemente suprir um agente terapêutico lipossomalmente encapsulado para um local alvo in vitro e in vivo para terapia anticâncer ou outra. O lipossama pode compreender uma solução tampão interna, contendo o agente terapêutico, a solução tendo um pH menor do que 6,5 e, muitíssimo preferivelmente, pH 3,5. Pelo menos parte dos íons cobre são retidos dentro da solução interna. Em uma forma de realização, o agente terapêutico pode ser um medicamento quimioterapêutico, tal como irinotecano. A invenção pode também compreender um ionóforo, para facilitar a carga do medicamento dentro do lipossoma. Em uma forma de realização particular, a combinação do ionóforo A23187 e cobre divalente encapsulado (Cu2+) resultou em uma formulação de irinotecano que exibiu atributos de retenção de medicamento surpreendentemente aperfeiçoados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61594304P | 2004-10-06 | 2004-10-06 | |
| PCT/CA2005/001536 WO2006037230A1 (en) | 2004-10-06 | 2005-10-06 | Liposomes with improved drug retention for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516265A true BRPI0516265A (pt) | 2008-08-26 |
Family
ID=36142279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516265-3A BRPI0516265A (pt) | 2004-10-06 | 2005-10-06 | composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8349360B2 (pt) |
| EP (1) | EP1796729A4 (pt) |
| JP (1) | JP4638500B2 (pt) |
| CN (1) | CN101072588B (pt) |
| AU (1) | AU2005291807B2 (pt) |
| BR (1) | BRPI0516265A (pt) |
| CA (1) | CA2582949A1 (pt) |
| WO (1) | WO2006037230A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5207169B2 (ja) * | 2007-10-18 | 2013-06-12 | 独立行政法人日本原子力研究開発機構 | 電離放射線分解性リポソーム、それを用いたリポソーム製剤、並びにリポソームの調整方法 |
| WO2010113983A1 (ja) | 2009-03-30 | 2010-10-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
| CN102369008B (zh) | 2009-03-30 | 2014-10-29 | 卫材R&D管理有限公司 | 脂质体组合物 |
| WO2011006510A1 (en) * | 2009-07-17 | 2011-01-20 | Technical University Of Denmark | Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines |
| SI3350222T1 (sl) | 2015-09-18 | 2022-01-31 | Technische Universitaet Muenchen | Ligandi za integrin avbeta6, sinteza in uporaba le-teh |
| WO2017100925A1 (en) * | 2015-12-15 | 2017-06-22 | British Columbia Cancer Agency Branch | Metal complexed therapeutic agents and lipid-based nanoparticulate formulations thereof |
| US10154947B2 (en) | 2016-01-06 | 2018-12-18 | The Procter & Gamble Company | Antiperspirant composition |
| US9730867B2 (en) | 2016-01-06 | 2017-08-15 | The Procter & Gamble Company | Methods of forming a slurry with microcapsules formed from phosphate esters |
| US9732303B2 (en) | 2016-01-06 | 2017-08-15 | The Procter & Gamble Company | Microcapsules formed from phosphate esters and compositions containing same |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| US11332498B2 (en) | 2017-03-17 | 2022-05-17 | Technische Universitat Munchen | Ligands for integrin αVβ8, synthesis and uses thereof |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| CA3183397A1 (en) | 2020-06-18 | 2021-12-23 | Daryl C. Drummond | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| CN116509803A (zh) * | 2022-01-21 | 2023-08-01 | 沈阳药科大学 | 外泌体分泌促进剂和光敏剂共载膜融合脂质体及其制备与应用 |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310506A (en) | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
| US5736155A (en) | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| MX9203808A (es) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5352435A (en) | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
| US5525232A (en) | 1990-03-02 | 1996-06-11 | The Liposome Company, Inc. | Method for entrapment of cationic species in lemellar vesicles |
| JPH06511470A (ja) * | 1991-07-03 | 1994-12-22 | ネクスター・フアーマシユーテイカルズ・インコーポレイテツド | 薬剤を含むリポソームの調製における充填技術 |
| AU4981896A (en) | 1995-02-14 | 1996-09-04 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering liposome-loadable drugs |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| CA2269758C (en) | 1996-10-22 | 2008-01-08 | Hermes Biosciences, Inc. | Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation |
| US5837282A (en) * | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
| US6106858A (en) | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
| US6723338B1 (en) * | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
| WO2001085131A2 (en) * | 2000-05-11 | 2001-11-15 | Celator Technologies Inc. | Lipid carrier compositions for improved drug retention |
| JP2004501955A (ja) * | 2000-06-30 | 2004-01-22 | アイネックス ファーマシューティカルズ コーポレイション | リポソーム抗新生物薬剤およびその使用 |
| JP2005519861A (ja) | 2001-07-27 | 2005-07-07 | ターゲサム・インコーポレーテッド | 治療剤及び撮像剤としての脂質構築物 |
| AU2002325120A1 (en) | 2001-09-10 | 2003-03-24 | Celator Technologies Inc. | Unilamellar vesicles stabilized with short chain hydrophilic polymers |
| AU2002331481B2 (en) * | 2001-10-03 | 2008-04-24 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| ES2272768T3 (es) | 2001-10-03 | 2007-05-01 | Celator Pharmaceuticals Inc | Composiciones para la administracion de combinaciones de farmacos. |
| GB2390953A (en) | 2002-07-15 | 2004-01-21 | King S College London | Controlling a micro cell transmit power to maintain quality of service for nearby devices served by an overlapping macro cell |
| JP2006511470A (ja) | 2002-09-10 | 2006-04-06 | 高砂香料工業株式会社 | 水中シリコーンエマルジョンを含む組成物ならびにそのような組成物を含む香料およびヘアケア調製物 |
| US20040265368A1 (en) * | 2003-04-02 | 2004-12-30 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| EP1608338A1 (en) | 2003-04-02 | 2005-12-28 | Celator Technologies Inc. | Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| EP1750673B1 (en) | 2004-05-17 | 2009-12-02 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
-
2005
- 2005-10-06 WO PCT/CA2005/001536 patent/WO2006037230A1/en not_active Ceased
- 2005-10-06 CA CA002582949A patent/CA2582949A1/en not_active Abandoned
- 2005-10-06 CN CN2005800419071A patent/CN101072588B/zh not_active Expired - Fee Related
- 2005-10-06 AU AU2005291807A patent/AU2005291807B2/en not_active Ceased
- 2005-10-06 US US11/576,595 patent/US8349360B2/en not_active Expired - Fee Related
- 2005-10-06 JP JP2007534983A patent/JP4638500B2/ja not_active Expired - Fee Related
- 2005-10-06 EP EP05791552A patent/EP1796729A4/en not_active Withdrawn
- 2005-10-06 BR BRPI0516265-3A patent/BRPI0516265A/pt not_active IP Right Cessation
-
2012
- 2012-12-09 US US13/709,005 patent/US8709474B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20110262524A1 (en) | 2011-10-27 |
| JP4638500B2 (ja) | 2011-02-23 |
| JP2008515817A (ja) | 2008-05-15 |
| US8709474B2 (en) | 2014-04-29 |
| AU2005291807B2 (en) | 2012-04-19 |
| WO2006037230A1 (en) | 2006-04-13 |
| US20130136790A1 (en) | 2013-05-30 |
| CA2582949A1 (en) | 2006-04-13 |
| AU2005291807A1 (en) | 2006-04-13 |
| US8349360B2 (en) | 2013-01-08 |
| EP1796729A4 (en) | 2010-12-08 |
| CN101072588A (zh) | 2007-11-14 |
| CN101072588B (zh) | 2012-11-28 |
| EP1796729A1 (en) | 2007-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0516265A (pt) | composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente | |
| Yu et al. | Butyrate modification promotes intestinal absorption and hepatic cancer cells targeting of ferroptosis inducer loaded nanoparticle for enhanced hepatocellular carcinoma therapy | |
| DE69531701D1 (de) | Sphingosome mit verbesserter arzneistoffabgage | |
| NO20014662D0 (no) | Fremgangsmåter og preparater for behandling av faste tumorer | |
| NZ541593A (en) | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | |
| AP1760A (en) | Platinum derivative pharmaceutical formulations. | |
| BR0115260A (pt) | Complexos de sn-38 com lipìdeos e seus usos no tratamento de doenças | |
| PT988056E (pt) | Metodos e composicoes de factor tecidual para o tratamento da coagulacao e de tumores | |
| BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
| ES2249888T3 (es) | Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer. | |
| PL371282A1 (en) | A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer | |
| BRPI0412798A (pt) | uso de uma combinação de um antagonista de fator de crescimento endotelial vascular e um agente antiproliferativo, método de inibir ou reduzir o crescimento de tumor, composição farmacêutica, uso de uma combinação de um antagonista de vegf e um agente quimioterapêutico, e, artigo de fabricação | |
| EP2301531A3 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
| BRPI0414014A (pt) | métodos para distribuição intradérmica de agentes terapêuticos | |
| BR0110837A (pt) | Quimioterapia de combinação | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| BRPI0413410A (pt) | co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer | |
| EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
| BRPI0406634A (pt) | Uso de um anagrelìdeo, anagrelìdeo na forma de base, ou um sal farmaceuticamente aceitável do anagrelìdeo, composição farmacêutica não-oral, e dispositivo médido para administração transdérmica | |
| WO2008049903A3 (en) | Wide-area parasystemic treatment of skin related conditions | |
| DK1276482T3 (da) | Kombinationskemoterapi | |
| Kirichenko et al. | Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration | |
| Dorr et al. | Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. | |
| ES2974073T3 (es) | Uso terapéutico del afatinib en el cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |